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Abstract
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors, commonly known as statins, may possess cancer
preventive and therapeutic properties. Statins are effective suppressors of cholesterol synthesis with a well-established risk-
benefit ratio in cardiovascular disease prevention. Mechanistically, targeting HMGCR activity primarily influences cholesterol
biosynthesis and prenylation of signaling proteins. Pravastatin is a hydrophilic statin that is selectively taken up by a
sodium-independent organic anion transporter protein-1B1 (OATP1B1) exclusively expressed in liver. Simvastatin is a
hydrophobic statin that enters cells by other mechanisms. Poorly-differentiated and well-differentiated cancer cell lines
were selected from various tissues and examined for their response to these two statins. Simvastatin inhibited the growth of
most tumor cell lines more effectively than pravastatin in a dose dependent manner. Poorly-differentiated cancer cells were
generally more responsive to simvastatin than well-differentiated cancer cells, and the levels of HMGCR expression did not
consistently correlate with response to statin treatment. Pravastatin had a significant effect on normal hepatocytes due to
facilitated uptake and a lesser effect on prostate PC3 and colon Caco-2 cancer cells since the OATP1B1 mRNA and protein
were only found in the normal liver and hepatocytes. The inhibition of cell growth was accompanied by distinct alterations
in mitochondrial networks and dramatic changes in cellular morphology related to cofilin regulation and loss of p-caveolin.
Both statins, hydrophilic pravastatin and hypdrophobic simvastatin caused redistribution of OATP1B1 and HMGCR to
perinuclear sites. In conclusion, the specific chemical properties of different classes of statins dictate mechanistic properties
which may be relevant when evaluating biological responses to statins.
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Introduction
Statins may be useful for the prevention and treatment of cancer
[1,2,3,4]. Statins were first isolated as fungal metabolites that
exhibited potent cholesterol lowering activity through the
inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase
(HMGCR) [5]. These compounds were soon recognized to lower
cholesterol through two systemic mechanisms. First, statins
reversibly inhibit HMGCR and thus reduce intracellular pools
of cholesterol. This results in an increase in low-density lipoprotein
(LDL)-receptors on cell surfaces leading to clearance and
catabolism of LDL [6]. Certain statins also inhibit hepatic LDL
production by preventing the synthesis of the LDL precursor,
VLDL [7]. The role of cholesterol in cancer progression remains
to be resolved but many tumor cell lines and tissues exhibit higher
levels of cholesterol than their normal counterparts [8,9]. Some
reports indicate that hypocholesterolemia occurs in cancer due to
increased use of cholesterol by tumors [10] whereas other reports
have associated lower tissue cholesterol with malignancy [11].
Statins prevent the rate-limiting conversion of HMG-CoA to
mevalonate by HMGCR, which is not only a precursor of
cholesterol but is an essential metabolite in the formation of
isoprenes. Isoprenes are critical compounds involved in the
prenylation of numerous signaling molecules such as small G
proteins [12]. Statin mediated inhibition of the prenylation process
is reversible by the addition of the various isoprenes such as
mevalonate, farnesyl-pyrophosphate, and geranyl-geranyl-pyro-
phosphate [12]. Prenylation also occurs in many cellular and
systemic regulatory pathways that are partly responsible for the
pleiotropic effects of statins [13]. Other pleiotropic effects may be
independent of prenylation or inhibition of cholesterol production
such as cell cycle arrest [14].
Epidemiological studies and meta-analyses of statin use and
cancer risk in the general population have provided conflicting
results. Some studies of cancers have shown risk reduction
associated with statin use [15,16,17] while other studies have
reported no effect from its use [18,19,20] or even an increased risk
[21].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28813The pharmacological features of statins are important in
understanding the role of statins in the treatment and prevention
of cancer [2,3,4]. The lipophilicity of statins and the presence or
absence of the transporter molecules on the cell surface can
influence the pharmacokinetics and intracellular distribution of
statins that affect bioactivity. Pharmacokinetic studies in rats and
humans have shown that hydrophilic statins such as pravastatin
primarily affect the liver [22,23]. In humans these liver specific
effects rely on a liver specific transporter:organic anion transporter
peptide (official gene designation SLCO1B1; official protein
designation OATP1B1) [24]. This gene is also known as SLC21A6
and the protein is also known as LST-1, OATP2, OATP-C, or
OATP6 [24]. The OATP1B1 transporter is involved in liver
specific uptake of pravastatin [25,26]. It is important to note that
genetic polymorphisms may also have a functional impact on
OATP/SLCO1B1 [27]. In contrast to hydrophilic statin phar-
macokinetic distribution, hydrophobic statins are readily distrib-
uted in many tissues [28]. We hypothesized that the hydrophobic-
simvastatin is expected to affect a wide variety of tumor cell lines
isolated from a variety of organ sites whereas hydrophilic-
pravastatin is expected to exhibit liver-specific effects on primary
cultures of hepatocytes and liver derived tumor cells. In this study
we present the comparative effects of pravastatin or simvastatin on
normal hepatocytes as well as in tumor cells isolated from a variety
of organ sites.
Materials and Methods
Chemicals
Hydrophilic pravastatin and hyrophobic simvastatin were
obtained from Calbiochem, San Diego, CA. Calcein acetoxy-
methyl (CAM) ester, MitoTracker Red CM-H2XRos, and 49-6-
diamidino-2-phenylindole (DAPI) were purchased from Molecular
Probes-Invitrogen Corporation, Carlsbad, CA. Acetonitrile, am-
monium acetate, and Triethylamine, all HPLC grade, were
purchased from Fisher (Pittsburgh, PA). Reagent grade formic acid
($95%), dimethylsulfoxide and additional chemicals were pur-
chased from Sigma Chemical Co. St Louis, MO.
Cell lines and cell cultures
Pairs of well-differentiated or poorly-differentiated cell lines that
originated in multiple tissue sites were obtained from American
Tissue Type Culture Collection (ATCC; Manassas, VA) including:
colon (Caco-2, HCT-116), pancreatic (Capan-1, MiaPaca), liver
(Hep G2, Hep 3B), breast (MCF-7, SKBr-3), prostate (LNCaP,
PC-3), bladder (U-9, U-14), skin (SCC-M7, SCC-P9) and lung
cancer (Calu-3, Calu-6) cell lines. Tumor cell lines from different
epithelial origins were grown in tissue culture according to ATCC
instructions. Normal human hepatocytes were purchased from
Cambrex BioScience (Walkersville, MD). Primary cell cultures
were maintained in defined hepatocyte growth medium according
to distributor’s instructions. Cell cultures were routinely tested for
mycoplasma by RNA/DNA hybridization (Gen-Probe, San
Diego, CA), and treated if needed with BM-Cyclin from Roche
(Indianapolis, IN).
Analysis of cell viability, apoptosis and mitochondrial
distribution by fluorescence microscopy
Apoptosis and nuclear morphology, DNA dye uptake, and
cellular staining were assessed by fluorescence microscopy. Cells
were plated in 96-well plates and treated with 0, 0.1, 1, 5, 10, and
20 mM pravastatin or simvastatin for 6 h, 24 h, 48 h, and 72 h.
Treatments were performed in 0.5% fetal bovine calf serum in the
appropriate medium. Cell viability was determined at each time
point by staining with vital dye CAM ester (2 mM) in phenol red
free DMEM for 15 minutes at 37uC. Cells were simultaneously
incubated with MitoTracker Red CM-H2XRos (1 mM), and DAPI
(1 ng/ml) Molecular Probes). Nuclear morphology, DNA dye
uptake, and cellular staining were assessed by fluorescence using
an Olympus IX-70 inverted microscope. Image acquisition was
achieved using a Quantix charged coupled device camera and IP
Labs software (Scanalytics, Inc., Fairfax, VA) on a Macintosh
computer (Apple Computer Corporation Cupertino CA).
Immunofluorescence analysis
Normal hepatocytes were established as monolayers on laminin-
coated coverslips to perform immunofluorescence studies. Cells
were treated with 10 mM pravastatin or simvastatin for 72 hr.
Cells were fixed in 1% paraformaldehyde and processed for
immunofluorescence studies as described before [29]. Briefly, cell
monolayers grown on cover slips were immunolabeled with anti-
OATP1B1, anti-p-cofilin (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-p-caveolin (BD Biosciences Pharmingen, San Jose, CA),
anti-HMGCR (Upstate Biotechnology, Lake Placid, NY) and
Alexa488 labeled secondary antibody; Molecular Probes, Eugene,
OR followed by counterstaining to detect DNA with DAPI and
actin Alexa 594-phalloidin (Molecular Probes, Eugene, OR). The
images were collected and analyzed as described above.
Cell proliferation assay
Cells were seeded in 96-well plates and treated with 0, 0.1, 1, 5,
10, and 20 mM pravastatin or simvastatin for 6 h, 24 h, 48 h, and
72 h. Proliferation was measured by treating cells with 40 mLo fa
phosphate buffered saline (PBS) solution containing 2.5 mg/mL 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
followed by removal of medium and solubilization of formazan
crystals with 100 mL dimethylsulfoxide. Plates were quantified by
reading absorbance at a wavelength of 540 nm on a 96-well
Spectramax M5-multiwell plate reader (Molecular Devices, Sunny-
vale, CA).
Reverse Transcriptase-Polymerase Chain Reaction
The RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX)
was used to extract the total RNA, which was treated with DNase I
prior to use in a reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis. One microgram of RNA was reverse
transcribed with mouse mammary tumor virus RT (Life Technol-
ogies, Inc., Rockville, MD). OATP1B1 565 bp sequences were
amplified by primer set OATP2-565F 59-ACTGATTCTC-
GATGGGTTGG-39 (forward) and OATP-565R 59-GTCCGGC-
AACTGATTTGTTT-39 (reverse). The 565 bp primer sets and
additional primer sets were designed and verified using Oligo 6.7
from Molecular Biology Insights (Cascade, CO). Primer pairs (59-
CAGCTCTGGAGAACTGCTG-39;5 9-GTGTACTCAGTCTC-
CACAGA-39) were used in RT-PCR analysis to detect GAPDH
mRNA.
Western Blot Analysis
Whole cell lysates were prepared as previously described [29].
Briefly, 50 mg of protein was loaded in each lane and run on a
NuPAGE Novex precast mini-gels (Invitrogen, Carlsbad, CA) and
transferred onto a nitrocellulose membrane (Schleicher & Schuell
Bioscience, Inc., Keene, NH). After blocking with 3% fatty acid
free-bovine serum albumin, the blots were exposed to antibodies
against OATP1B1 or HMGCoA-reductase (Upstate Lake Placid,
NY), followed by the appropriate secondary antibody (Pierce
Hydrophilic/Phobic Statins and Tumor Cell Growth
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an enhanced chemiluminescence system (Pierce).
Uptake of Statins by high performance chromatography
and Tandem mass spectrometry (LC/MS/MS)
Statins were analyzed using a modification of previously
published methods [30]. After 6 hr of treatment with pravastatin
and simvastatin, hepatocyte and PC-3 cells were washed with cold
PBS and scraped free in the presence of a lysis buffer containing
20 mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM NaF,
40 mM b-glycerophosphate, 20 mM sodium pyruvate, 0.5%
Triton X-100, and 1 mM sodium orthovanadate with protease
inhibitor cocktail (Sigma). Cell lysates were then sonicated on ice
for 3 minutes and transferred to glass tube (136100 mm).
Additional 150 ml of PBS were added to the samples followed by
addition of an aliquot of 20 ml of 1 N citric acid. Statins were
extracted with 2 ml of ethyl acetate three times. The upper
organic phases were pooled and evaporated to dryness under a
stream of nitrogen at room temperature. Samples were then
reconstituted with 100 ml of 80% of 20 mM ammonium acetate in
0.02% formic acid and 20% acetonitrile before being analyzed by
LC/MS/MS. Protein levels were quantified via the DC protein
assay (BioRad, Inc., Hercules, CA).
Pravastatin and simvastatin were detected using a Quatro
Ultima mass spectrometer (Waters Corp., Milford, MA) equipped
with an Agilent 1100 binary LC inlet. Statins were separated using
a Hypersil GOLD C18 3 mm column (5062.1 mm; Thermo
Electron, Bellefonte, PA). The mobile phase consisted of 20 mM
ammonium acetate, 4 mM triethylamine, and 0.02% formic acid
in DI water (solution A) and acetonitrile (solution B). The flow rate
was set at 300 ml/minute with a column temperature of 50uC. The
gradient for separating the two statins was as follows: 0–2 min. at
90% A, 2 to 2.1 min. linear increase to 100% B, 2.1 to 5 min at
100% B, 5 to 5.1 min. back to 90% A, 5.1 to 9 min. 90% A. The
sample injection volume was 25 ml with samples being kept at
18uC in a refrigerated autosampler.
Pravastatin and simvastatin were detected using electrospray
negative ionization mode, cone voltage was 60 V, cone gas flow
70 L/hour, and desolvation gas flow at 700 L/hour. Desolvation
temperature was 350uC, and the source temperature was 125uC.
Fragmentation of all compounds was performed using argon as the
collision gas at a cell pressure of 2.1610
23 torr with collision
energy setting of 18. Statins were detected using multiple-reaction
monitoring of the transition ions 423.40.303.2 and 435.4.319.2
for pravastatin and simvastatin, respectively. Statin concentrations
were normalized to the protein content in the samples.
Data Treatment and Statistical Analysis
Two-way ANOVAs, followed by Tukey’s test, were used with
the factors cell type and treatment (SAS 9.2; SAS Institute, Cary,
NC). Statistical significance was set at p,0.05.
Results
Hydrophobic-simvastatin inhibits tumor cell growth
more effectively than hydrophilic-pravastatin
Based on MTT assays, simvastatin effects were more pro-
nounced than pravastatin on the growth of all the tumor cell lines
examined except for squamous cancer cell line SCCM7 and
pancreatic cancer cell line Capan-1(Figure 1). The cell lines tested
included malignant colon, pancreatic, prostate, bladder, skin and
lung. All experiments were conducted for 72 hours except for the
most sensitive cell line Panc 28, which was responsive at 24 hours.
Simvastatin exhibited a dose and time dependent inhibition of
cancer cell growth, while pravastatin showed minimal or no effect
on all of the cancer cell lines studied. Unexpectedly, the typical
response to simvastatin was greater in poorly-differentiated cells
when compared to the well-differentiated cells as shown in figure 1.
Simvastatin causes extensive cell shape change and
mitochondrial redistribution within hours in highly
responsive cancer cells
Image analysis of cells stained with three fluorescent markers
was carried out at 1, 6 and 24 h after treatment with 10 mM
simvastatin. Calcein AM is a cell permeable vital dye that is
cleaved by non-specific esterases to become impermeable to the
intact cell membrane and emits a bright green fluorescence.
MitoTracker Red CM-H2XRos is a reduced, non-fluorescent dye
that emits bright red fluorescence upon oxidation. This dye also
stains mitochondria in live cells and its accumulation is dependent
upon membrane potential. DAPI readily enters cells when plasma
membrane integrity is lost and specifically labels nuclei. Exami-
nation of two highly sensitive cell lines, PC-3 and Panc 28,
illustrate how extensively these cell lines change shape in response
to 10 mM simvastatin over a 24 h time period. These changes in
cell shape are accompanied by a significant redistribution of
mitochondria that initially migrate into cellular processes and
coalesce into perinuclear deposits. Panc 28 cells displayed the
highest response by extending cellular processes as early as 1 h, a
behavior that became more extensive at 6 h and 24 h (Figure 2A).
A significant number of Panc28 cells were dead by 24 h. PC-3 cells
exhibited similar but less extensive shape changes and behavior
over the same time frame (Figure 2B).
Simvastatin but not pravastatin induced morphological
changes and death of tumor cells at 48 h and 72 h
Pravastatin treatment at 20 mM for longer time periods of 48 h
(data not shown) and 72 h (Figure 3) had no effect on any tumor
cells. In contrast, simvastatin at 48 h and 72 h caused cells to
retract their processes and lose plasma membrane integrity
(Figure 3). Increased membrane permeability led to leakage of
CAM in conjunction with the influx of DAPI. DAPI labeling of
DNA illustrated nuclear condensation indicative of apoptosis.
Shrinkage of the central cell body around the nuclei and apoptotic
body formation is seen at the plasma membrane.
The expression of HMGCR does not consistently
correspond to statin responsiveness
Since HMGCR activity is regulated by statins, total protein
isolated from cells was examined by Western blot analysis for
HMGCR expression (Figure 4A). The majority of cells derived
from a given tissue expressed HMGCR at relatively similar levels
regardless of differentiation status, such as pancreatic carcinoma
cells (Capan 1, lane 4; MiaPaca, lane 5), breast (MCF-7, lane 10;
SkBr3, lane 11), colon (Caco 2, lane 12; HCT116, lane 13),
bladder (U9, lane 14; U14, lane 15), or squamous cell carcinoma
(SCC-P9, lane 16; SCC-M7, lane 17). In other instances, there
were differences in HMGCR expression between well-differenti-
ated and poorly-differentiated cells, as observed in liver hepato-
carcinoma cells (HepG2, lane 2; and Hep3B, lane 3), and lung
(Calu3, lane 8; Calu6, lane 9). In the prostate, PC-3 cells (lane 7)
expressed high levels of HMGCR and responded to statins,
whereas LnCAP cells (lane 6) with only traces of HMGCR
remained unresponsive to statins. These data suggest that the
expression levels of HMGCR in tumor cells do not always
correspond to responsiveness to statin treatment and that other
factors may be involved.
Hydrophilic/Phobic Statins and Tumor Cell Growth
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28813Figure 1. Comparison of the effects of hydrophilic-pravastatin and hydrophobic-simvastatin on normal hepatocytes and cancer
cells. The effects of pravastatin and simvastatin on liver hepatocytes and tumor cells was determined by MTT assay and are represented as a percent
of the control absorbance at a wavelength of 540 nm. All data were performed at 72 h except for Panc 28 which was responsive at 24 h. Data shown
are from representative experiments (n=8; except colon, n=4). Values are expressed as mean+SD. * p,0.05, significant difference between control
and simvastatin or pravastatin groups. " p,0.05, significant difference between simvastatin and pravastatin groups. # p,0.05, significant difference
between well differentiated and poorly differentiated cell types.
doi:10.1371/journal.pone.0028813.g001
Figure 2. Simvastatin induced shape change and mitochondrial redistribution in cancer cells at early time points. PC-3 prostate cells
and Panc 28 pancreatic cells were treated with 10 uM simvastatin and stained with calcein AM (green), MitoTracker CM-H2XRos, a reduced, non-
fluorescent dye that fluoresces (red) upon oxidation, and DAPI, a staining dye that emits (blue) when bound to DNA. These images of PC-3 and Panc
28 were acquired via fluorescence microscopy and illustrate that changes in cell shape occurred within 6 hours becoming more extensive by 24 h.
These shape changes were accompanied by a significant redistribution of mitochondria.
doi:10.1371/journal.pone.0028813.g002
Hydrophilic/Phobic Statins and Tumor Cell Growth
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28813Normal hepatocytes but not tumor cells express OATP1B1
Liver-specific organic anion transporter protein OATP1B1 was
examined in normal liver hepatocytes and all of the other tumor cell
lines since it was reported to mediate liver specific uptake of pravastatin
[25]. Normal human liver and normal hepatocytes were the only
samples to specifically express OATP1B1 mRNA (Figure 4B) or
OATP1B1 protein (Figure 4C). All other tumor cells did not express
OATP1B1 mRNA (Figure 4B) or OATP1B1 protein at detectable
levels (Figure 4C). Although PCR amplimers were sometimes observed
in pancreatic samples (lane 6), further analysis of total RNA by RT-
PCR using primers to other regions of OAT-P1B1 revealed specific
products only in the human liver tissue and liver hepatocytes.
Normal hepatocytes incorporate hydrophilic-pravastatin
more effectively than tumor cells
LC/MS/MS analytical methods were developed to achieve critical
separation and identification of pravastatin and simvastatin (Figure 5A
and 5B). Mass spectroscopy analysis was done using standards as
internal controls to establish separation parameters for pravastatin and
simvastatin (Figure 5B). Analysis of statin uptake by normal human
hepatocytes or selected tumor cells was performed to determine if
OATP1B1 expression correlated with drug incorporation. Cells were
seeded on 10 cm dishes and treated overnight with 10 mM pravastatin
or 10 mM simvastatin. Cells were lysed and subjected to extraction
and determination of pravastatin and simvastatin by LC/MS/MS
analysis (Figure 5B and 5C). Human hepatocytes incorporated
significantly higher (86 fold) levels of pravastatin (1.55 ng/mg)
compared to PC-3 prostate cancer cells (0.018 ng/mg) on a per
milligram basis. The difference in hydrophobic-simvastatin uptake
between hepatocytes (2.42 ng/ml) compared to PC-3 tumor cells
(1.40 ng/ml) was only 1.72 times higher (Figure 5D).
Normal hepatocytes respond to both pravastatin and
simvastatin
Both pravastatin and simvastatin suppressed the growth of
OATP1B1 expressing hepatocytes to nearly the same extent
Figure 4. 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) expression varies between cells but the organic anion
transporter (OATP) is expressed exclusively in normal liver. A) HMGCR was examined by Western analysis for its expression as follows: liver
(normal hepatocytes, lane 1; HepG2, lane 2; Hep3B, lane 3), pancreas (Capan 1, lane 4; Mia Paca, lane 5), prostate (LnCap, lane 6; PC-3, lane 7), lung
(Calu3, lane 8; Calu6, lane 9), breast (MCF-7, lane 10; SkBr3, lane 11), colon (Cacao 2, lane 12; HCT116, lane 13), bladder (U9, lane 14; U14, lane 15), or
squamous cell carcinoma (SCCP9, lane 16; SCCM7, lane 17). These data illustrate that HMGCR expression does not correspond to drug response. B)
Total RNA isolated from human liver tissue (lane L) or cells and analyzed for expression of a 565 bp amplimers from OATP. The numeric sequence of
PCR samples is the same as described for protein in A. GAPDH primers were used on the same series of mRNA samples to determine the quality and
loading consistency of PCR products. Only whole liver (L) and hepatocytes (1) expressed multiple OATP amplimers by PCR. Note: PCR amplimers
observed in pancreatic samples (lane 6) were not present when other HMGCR primer sets were used. C) Western analysis revealed OATP protein only
in the human liver hepatocytes in lane 1. Tumor cell total protein was examined in the same sequence as in A and did not reveal any OATP protein.
doi:10.1371/journal.pone.0028813.g004
Figure 3. Simvastatin but not pravastatin dose-dependently induces morphological changes and apoptotic behavior in responsive
tumor cells. Image analysis of cells stained with three fluorescent markers calcein AM (green), DAPI (blue), and MitoTracker Red CM-H2XRos (red),
was performed as described in the methods section. Tumor cells were examined at 72 h except in the case of Panc 28 which were processed at 24 h.
doi:10.1371/journal.pone.0028813.g003
Hydrophilic/Phobic Statins and Tumor Cell Growth
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28813Figure 5. Incorporation and growth response of normal hepatocytes or tumor cells to hydrophilic-pravastatin or hydrophobic-
simvastatin. A & B) Total ion chromatography methods were developed to attain critical separation profiles showing pravastatin and simvastatin. C)
Mass spectroscopy was performed by using deuterated standards as internal controls for separation to distinguish between statins. Statins were
detected by using electrospray-negative ionization and monitoring by magnetic resonance microscopy. Fragmentation of the statins were performed
using argon as the collision gas at a collision cell pressure of 2.1610
23 torr. D) LS/MS/MS determination of statins. Monolayers of normal hepatocytes
or prostate cancer cells (PC-3) were placed in fresh serum-free medium before the addition of 10 mM pravastatin or simvastatin. Cell culture medium
and cells were collected 6 h after treatment. The statins were subjected to solid-phase extraction and analyzed for the presence of pravastatin or
simvastatin by LC/MS/MS analysis. Data represent two determinations run in duplicate. E) Effects of pravastain and simvastatin on OATP expressing
human hepatocytes were determined by MTT assay and are represented as a percent of the control absorbance at a wavelength of 540 nm. Data
shown are from representative experiments (n=8). These data illustrate that both pravastatin and simvastatin suppressed the growth of hepatocytes
Hydrophilic/Phobic Statins and Tumor Cell Growth
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than pravastatin, which correlated with their effects on suppres-
sion. In contrast, tumor cells, which lack OATP1B1 failed to
incorporate and did not respond to pravastatin but were growth
suppressed by simvastatin (Figure 1). These data illustrate that
uptake of pravastatin by OATP1B1 expressing normal hepatocytes
correlated with changes in growth and behavioral responses that
were absent from tumor cells, which lack OATP1B1 expression.
Pravastatin as well as simvastatin causes relocalization of
OATP1B1 to the perinuclear space in hepatocytes
Prior to treatment with statins, OATP1B1 was diffusely
distributed in hepatocytes (Figure 6A, top row). After treatment
with pravastatin (Figure 6A, middle row) or simvastatin (Figure 6A,
bottom row) OATP1B1 progressively became distributed in the
perinuclear space of the cell cytoplasm.
Pravastatin and simvastatin cause altered distribution of
HMGCR in hepatocytes
HMGCR distribution was diffuse in control hepatocytes
(Figure 6B, left column). After treatment with pravastatin
(Figure 6B, middle row) or simvastatin (Figure 6B, bottom row)
for 72 h, HMGCR distribution condensed within the perinuclear
space in areas resembling the endoplasmic reticulum.
Pravastatin as well as simvastatin disrupt caveoli in
hepatocytes
Inhibition of cholesterol synthesis following statin treatment was
expected to disrupt caveoli. Immunofluorescent detection of pY-
14-caveolin was examined to determine if statin treatment was
capable of disrupting caveoli (Figure 6B, middle column). The
observed distribution of pY-14-caveolin in control hepatocytes
illustrated the membrane clusters of phospho-protein that were
extensively associated with actin filaments. Treatment of hepato-
cytes with pravastatin (Figure 6B, middle row) or simvastatin
(Figure 6B, bottom row) for 72 h illustrated the loss of pY-14-
caveolin that coincided with the cytoplasmic process extension and
subsequent change in cell shape.
Pravastatin and simvastatin cause clustering of phospho-
cofilin in hepatocytes
Since prenylation of proteins such as G-proteins, Rac and Rho,
are affected by statin treatment [12], we examined the
downstream target cofilin to determine the effects of statins on
its phosphorylation state (Figure 6B, right column). Cofilin
phosphorylation on serine 3 was very diffuse in control cells but
formed extensive clusters after treatment of hepatocytes with
pravastatin (Figure 6B, middle row) or simvastatin (Figure 6B,
bottom row). These data suggest that changes in cell morphology
that occur during responses to statins may involve cofilin-mediated
mechanisms.
Discussion
We tested the hypothesis that cell type specific uptake of statins
influences responsiveness to the drug. We expected hydrophobic-
simvastatin to inhibit a wide variety of tumor cell lines compared
to hydrophilic-pravastatin which was expected to exhibit
liver-specific effects. Hydrophilic-pravastatin was ineffective at
inhibiting the growth or altering the biologic behavior of any
tumor cell line. Normal hepatocytes were the only cells examined
that expressed OATP1B1, a liver specific transporter molecule
capable of taking up hydrophilic-pravastatin. Uptake of hydro-
philic-pravastatin by normal hepatocytes initiated changes in
cellular morphology and caused growth arrest. Neither HepG2
nor Hep3B hepatocarcinoma cells expressed OATP1B1. Thus,
neither was able to respond to hydrophilic-pravastatin. In contrast,
hydrophobic-simvastatin inhibited the growth of a wide variety of
tumor cells in a dose-dependent manner. Unexpectedly, hydro-
phobic-simvastatin inhibited the growth of cells generally thought
to be poorly-differentiated more effectively than those thought to
be well-differentiated. Growth inhibition by hydrophobic-simvas-
tatin was accompanied by extensive morphological changes and
the redistribution of mitochondria at early time points of 1 h, 6 h
and 24 h. Treatments of poorly-differentiated tumor cells for
longer time periods 48 h and 72 h caused extensive cell death that
was less apparent in the well-differentiated tumor cells.
The expression of OATP1B1 occurs exclusively in normal liver
on the basolateral (sinusoidal) plasma membrane of hepatocytes
and has 12 transmembrane domains [31]. The role OATP1B1
plays in liver function is to drive the hepatic clearance of albumin-
bound amphipathic organic compounds [32]. Studies on tissue
samples revealed decreased levels of OATP1B1 in hepatocellular
carcinoma tumor samples when compared to normal liver [33,34].
We observed the absence of detectable levels of OATP1B1
expression by western blot in HepG2 and Hep3B hepatocarcino-
ma cells, which may explain the lack of response to pravastatin
(Figures 1 and 4). Other reports have shown that OATP1B1
expression was lower in HepG2 cell lines compared to normal
hepatocytes [33,35]; however we are unaware of similar
observations in Hep3B cells. Other studies on HepG2 cells have
shown that pravastatin had less of an effect on cholesterol synthesis
than either simvastatin or lovastatin [36]. These results are
consistent with our observations of differential inhibition of cell
growth in HepG2 and Hep3B hepatocarcinoma cells. Only one
other report that we are aware of has examined OATP1B1 in a
limited number of tumor cells by RT-PCR [37]. These findings
are in line with our observations on the absence of detectable
expression levels of OATP1B1 in the tumor cell lines tested.
The OATP1B1 protein exhibits a broad range of transport
substrates that includes bile salts, bilirubin, bromosulphophthalein,
steroid conjugates, the thyroid hormones T4 and T3, eicosanoids,
cyclic peptides, and toxins such as microcystin and phalloidin [38].
It also transports many drugs including benzylpenicillin, metho-
trexate, rifampicin, and most notably pravastatin. Pravastatin is
hydrophilic due to the presence of the hydroxyl group attached to
its decalin ring, whereas simvastatin has a methyl group
substituted in this position making it hydrophobic. The hydro-
philic nature of pravastatin accounts for its minimal penetration
into the intracellular space of nonhepatic tissues and does not
accumulate in plasma due to first-pass hepatic elimination even
with repeated administration [39]. Pharmacokinetic studies have
shown that pravastatin is preferentially taken up by liver tissue
[23]. The uptake of pravastatin was observed to be OATP1B1
mediated in normal human hepatocytes but not in HepG2 cells
[36]. Compared to hydrophilic-pravastatin, hydrophobic-simvas-
tatin is taken up in many tissues in a less selective fashion. Koga
et al [23] showed pravastatin inhibited sterol synthesis by 90% in
the liver and ileum of rodents but less than 14% in kidney, spleen,
to nearly the same extent. Values are expressed as mean+SD. * p,0.05, significant difference between control and simvastatin or pravastatin groups.
" p,0.05, significant difference between simvastatin and pravastatin groups.
doi:10.1371/journal.pone.0028813.g005
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simvastatin inhibited this process in all tissues. Our observations
using LC/MS/MS analysis were consistent with these findings
(Figure 5 A–D). Hepatocytes actively incorporated both prava-
statin and simvastatin by 6 h and responded to both treatments to
the same extent by 72 h (Figure 5E). In comparison, PC-3 prostate
cancer cells incorporated far less pravastatin by 6 h (Figure 5 A–D)
and were less growth inhibited by 72 h in tissue culture (Figure 1).
This was confirmed by LC/MS/MS analysis where the presence
of the transporter in hepatocytes accounted for an 86-fold increase
in pravastatin uptake as compared to PC3 cells. The response of
PC-3 cells by 72 h is likely indicative of pravastatin incorporation
by passive diffusion since the drug remained in tissue culture over
the full 72 h treatment period and therefore was not subjected to
systemic first-pass hepatic elimination. In fact, PC-3 and CaCo2
cells were the only lines to exhibit any type of noteworthy response
to pravastatin treatment (fig. 1).
We observed a two-phased response in tumor cells to
hydrophobic-simvastatin treatment. The first phase involved a
dramatic change in cell morphology within the first 6 h to 24 h. In
Figure 6. OATP and HMGCR redistribution, loss of p-caveolin and clustering of p-cofilin in statin treated cells. A) OATP
immunofluorescent labeling (green) is observed diffusely distributed over the surface of untreated hepatocytes but becomes more perinuclear in
cells treated with hydrophilic-pravastatin or lipophilic-simvastatin. Cells were counterstained for actin using alexa-594-phalloidin (red) and nuclear
DNA using DAPI (blue). Actin redistribution occurs in conjunction with cellular elongation. B) HMGCR immunofluorescent labeling (left column,
green) was diffusely distributed within untreated hepatocytes but became more perinuclear in cells treated with hydrophilic-pravastatin or lipophilic-
simvastatin. Cells were counterstained for actin using alexa-594-phalloidin (red) and nuclear DNA using DAPI (blue). P-Tyr14-caveolin (green)
expression was lost following statin treatment (middle column). P-Ser3-cofilin (green) formed clusters following statin treatment (right column).
doi:10.1371/journal.pone.0028813.g006
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early phase (figure 2). The second phase of the response occurred
between 24 h to 72 h, which involved the loss of plasma
membrane integrity. The early phases of growth arrest appear to
involve isoprenylation of small G. proteins. The prenylation
process seems to have effects on the biology of individual cells prior
to cholesterol depletion and is reversible by the addition of the
various isoprenes such as mevalonate, farnesyl-pyrophosphate, and
geranyl-geranyl-pyrophosphate [12].
The second phase of cellular response to hydrophobic-
simvastatin involves cholesterol depletion. At the cellular level,
this can reduce the content of lipid rafts [40] as well as the
expression of caveolin-1 [41,42]. This protein is involved in the
formation and regulation of caveolae which are membranous pits
that play a role in cellular transport, signaling and cancer [43].
Caveolin can be phosphorylated on tyrosine 14 by Src to form
dimers that initiate interactions with the actin cytoskeleton and
maintain the structural organization of caveoli [44,45]. Inhibition
of cholesterol synthesis ultimately leads to the induction of
apoptosis [46]. We observed downregulation of pY14-caveolin
following treatment with either pravastatin (Figure 6B, middle
row) or simvastatin (Figure 6B, bottom row) indicative of loss of
actin interactions. This coincided with the changes in membrane
structure associated with process extension and the change in cell
shape, a likely effect of statins on small G proteins. Downstream of
G-protein activation lies cofilin, an actin-binding protein involved
in the regulation of cell shape and motility [47]. Previous studies
have shown that cofilin phosphorylation at serine3 leads to loss of
actin binding and severing activities. Cell shape changes and
motility require cofilin activation at the leading edge and
inactivation in other areas. Taken together, these data implicate
the involvement of cofilin-mediated mechanisms in the morpho-
logical changes that occur during response to statins (Figure 6B).
These data also suggest that the eventual loss of cholesterol in
combination with prolonged loss of isoprenylation of signaling
factors contribute to morphological changes that ultimately lead to
cell death (Figure 6B). These observations corroborate and present
additional information to the mechanism of action of statins
presented by Gruruswamy et al., in colon cancer cells [42].
Systemic effects of statins are more complex. When the serum
cholesterol decreases, a compensatory increase in tissue mevalo-
nate occurs in the extra-hepatic tissue [48]. Duncan et al., have
shown that mevalonate promotes the growth of tumors derived
from human breast cancer cells in mice [49]. Since simvastatin
uptake into extra-hepatic tissue occurs through passive diffusion,
such deleterious effects are not expected to occur with the
lipophilic statins like simvastatin since mevalonate is depleted in
extra-hepatic tissue as well. This corroborates with the observation
from epidemiological studies of a lack of adverse effects in terms of
cancer risk with the lipophilic statins [50,51]. A decrease risk of
cancer has been noted with the use of the lipophilic statins,
simvastatin [52] [17] and lovastatin [51]. On the other hand, the
uptake of pravastatin is dependent on the presence of a OATP1B1
[39]. This transporter is not present in extra-hepatic tissue and
therefore pravastatin is able to inhibit HMGCR in liver and ileum
only where the transporter is present [23]. This leads to an
increase in mevalonate synthesis in extra-hepatic tissue and
promotes tumor growth of neoplastic cells [23]. This finding
may explain the increased incidence of cancers noted in some
epidemiological studies with pravastatin [53,54]. Hence epidemi-
ological studies have to identify the class of statins being analyzed
for cancer risk reduction before determining their efficacy. In an
editorial in the Journal of Clinical Oncology, Kim points out that the
association of statin use and cancer risk based on currently
published epidemiologic studies and meta-analyses of cancer risks
in clinical trials, is inconclusive at its best and that there are no
effects at its worst [18]. The recently published epidemiological
studies by Jacobs et. al., [20] and Dale et. al., [19], as well as others
[17,55,56] do not adequately consider this important pharmaco-
logical distinction in their analysis. Jacobs et. al., (28) showed no
positive effect of statins on cancer risk in a large population of
132,000 men and women in the Nutrition Cohort of the ACS
Prevention Study II (CPS-II). The authors point out that a small
reduction in risk or an effect of a specific type or dose of statin
cannot be ruled out. This study is in marked contrast to the
Molecular Epidemiology of Colorectal Cancer (MECC) study in
Northern Israel [15], which showed a 47% relative risk reduction
in the incidence of colon cancer irrespective of the class of statin
used. As outlined by McLaughlin [57] in an editorial, accompa-
nying the Dale et. al., [19] study, future epidemiological studies
should draw information not only from large cohorts through self-
report but these data should be verified through pharmacy data-
bases and population-based cancer registries to obtain details of
drug dose, regimes, class of drugs and cancer type and stage.
Furthermore, recent reports suggest that associations between
statin use and the occurrence of cancer remain inconclusive [58].
The general consensus seems to be that cancer incidence should
continue to be monitored among statin users and that longer-
latency effects remain possible [58].
In vitro experiments with statins have shown significant effects on
cell growth and proliferation. We have shown significant
differential effects of simvastatin and pravastatin on cell growth
and apoptosis in a variety of malignant cancer cell lines. The
lipophilic class of statins have profound effects on cell growth and
apoptosis in a variety of malignant cell lines. Furthermore, these
effects appear to be more profound in poorly-differentiated cancer
cell lines. We believe that these differential effects are due to the
inability of hydrophilic pravastatin to achieve adequate intracel-
lular concentrations since all malignant cell lines examined lack
the expression of the transporter protein required to transport
pravastatin into the cell. Regardless of the fact that the statin
concentration range used in these experiments is above those
observed in clinical pharmacodynamic studies [59], the findings
presented here have implications for interpretation and conduct of
epidemiological, prevention and treatment studies on the use of
statins in cancer. The type and dose of statins used would be
important to analyze in epidemiological studies. Based on our
findings, we believe that the data from epidemiological studies
reported so far do not provide us sufficient ground to eliminate
statins as potential chemopreventive or therapeutic agents. Even if
the lipophilic statins are not considered to be useful as preventive
agents, we have shown the potent cytotoxic properties of the
lipophilic class of statins. This may suggest a role for lipophilic
statins in the treatment of malignancies in conjunction with other
cytotoxics or biological agents. Further studies of the lipophilic
class of statins in animal models are necessary to test their efficacy
and potential role in cancer therapy or prevention.
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